| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Gynecologic Surgical Procedures | 72 | 2023 | 356 | 15.720 |
Why?
|
| Uterine Cervical Neoplasms | 112 | 2024 | 1833 | 15.430 |
Why?
|
| Genital Neoplasms, Female | 63 | 2024 | 735 | 12.200 |
Why?
|
| Hysterectomy | 61 | 2023 | 611 | 8.380 |
Why?
|
| Laparoscopy | 57 | 2023 | 1225 | 7.040 |
Why?
|
| Endometrial Neoplasms | 37 | 2023 | 1341 | 5.490 |
Why?
|
| Ovarian Neoplasms | 60 | 2024 | 4638 | 4.730 |
Why?
|
| Robotics | 25 | 2024 | 359 | 4.480 |
Why?
|
| Minimally Invasive Surgical Procedures | 31 | 2023 | 500 | 4.240 |
Why?
|
| Lymph Node Excision | 44 | 2024 | 1959 | 3.540 |
Why?
|
| Lymph Nodes | 30 | 2024 | 2967 | 2.960 |
Why?
|
| Gynecology | 11 | 2022 | 217 | 2.870 |
Why?
|
| Female | 310 | 2024 | 141928 | 2.540 |
Why?
|
| Fertility Preservation | 13 | 2021 | 150 | 2.350 |
Why?
|
| Sentinel Lymph Node Biopsy | 20 | 2024 | 1415 | 2.210 |
Why?
|
| Carcinoma, Squamous Cell | 35 | 2023 | 5437 | 2.100 |
Why?
|
| Sentinel Lymph Node | 8 | 2023 | 216 | 2.090 |
Why?
|
| Indocyanine Green | 7 | 2024 | 117 | 2.020 |
Why?
|
| Cytoreduction Surgical Procedures | 12 | 2023 | 475 | 1.910 |
Why?
|
| Humans | 320 | 2024 | 261506 | 1.860 |
Why?
|
| Trachelectomy | 11 | 2021 | 28 | 1.830 |
Why?
|
| Uterine Neoplasms | 12 | 2023 | 545 | 1.810 |
Why?
|
| Cervix Uteri | 10 | 2022 | 253 | 1.800 |
Why?
|
| Neoplasm Recurrence, Local | 45 | 2023 | 10035 | 1.780 |
Why?
|
| Neoplasm Staging | 80 | 2023 | 13658 | 1.770 |
Why?
|
| Adenocarcinoma | 31 | 2023 | 7789 | 1.740 |
Why?
|
| Fallopian Tube Neoplasms | 9 | 2017 | 153 | 1.680 |
Why?
|
| Medical Oncology | 11 | 2024 | 1423 | 1.680 |
Why?
|
| Pain, Postoperative | 8 | 2022 | 610 | 1.680 |
Why?
|
| Lymphatic Metastasis | 30 | 2024 | 4844 | 1.660 |
Why?
|
| Venous Thromboembolism | 7 | 2023 | 335 | 1.600 |
Why?
|
| Perioperative Care | 8 | 2023 | 451 | 1.570 |
Why?
|
| Adult | 160 | 2023 | 77950 | 1.520 |
Why?
|
| Conization | 7 | 2022 | 36 | 1.500 |
Why?
|
| Vulvar Neoplasms | 10 | 2021 | 236 | 1.500 |
Why?
|
| Coloring Agents | 7 | 2017 | 234 | 1.490 |
Why?
|
| Postoperative Complications | 33 | 2023 | 5542 | 1.480 |
Why?
|
| Carcinoma, Adenosquamous | 12 | 2021 | 103 | 1.470 |
Why?
|
| Length of Stay | 21 | 2023 | 1900 | 1.440 |
Why?
|
| Pelvic Exenteration | 11 | 2021 | 108 | 1.410 |
Why?
|
| Neoplasms, Glandular and Epithelial | 11 | 2017 | 519 | 1.400 |
Why?
|
| Fellowships and Scholarships | 4 | 2015 | 390 | 1.390 |
Why?
|
| Middle Aged | 155 | 2023 | 86204 | 1.340 |
Why?
|
| Carcinoma | 13 | 2021 | 2578 | 1.270 |
Why?
|
| Retrospective Studies | 95 | 2023 | 37905 | 1.250 |
Why?
|
| Aged | 128 | 2023 | 70117 | 1.220 |
Why?
|
| Analgesics, Opioid | 9 | 2022 | 1371 | 1.210 |
Why?
|
| Peritoneal Neoplasms | 12 | 2019 | 821 | 1.180 |
Why?
|
| Laparotomy | 11 | 2018 | 211 | 1.160 |
Why?
|
| Bibliometrics | 3 | 2023 | 71 | 1.120 |
Why?
|
| Aged, 80 and over | 72 | 2023 | 29902 | 1.120 |
Why?
|
| Pelvis | 10 | 2023 | 362 | 1.090 |
Why?
|
| Young Adult | 54 | 2021 | 21445 | 1.050 |
Why?
|
| Patient Reported Outcome Measures | 8 | 2023 | 799 | 0.960 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 4 | 2017 | 108 | 0.920 |
Why?
|
| Robotic Surgical Procedures | 9 | 2024 | 481 | 0.890 |
Why?
|
| Access to Information | 1 | 2023 | 65 | 0.890 |
Why?
|
| Salpingectomy | 3 | 2016 | 43 | 0.840 |
Why?
|
| Conservative Treatment | 3 | 2021 | 58 | 0.840 |
Why?
|
| Intraoperative Complications | 5 | 2019 | 301 | 0.810 |
Why?
|
| Patient Selection | 4 | 2024 | 2055 | 0.800 |
Why?
|
| Treatment Outcome | 51 | 2023 | 32848 | 0.800 |
Why?
|
| Heart Neoplasms | 2 | 2020 | 214 | 0.800 |
Why?
|
| Blood Loss, Surgical | 9 | 2019 | 309 | 0.790 |
Why?
|
| Carcinoma, Endometrioid | 6 | 2017 | 323 | 0.780 |
Why?
|
| Optical Imaging | 3 | 2017 | 157 | 0.780 |
Why?
|
| Neoplasm Micrometastasis | 2 | 2023 | 49 | 0.770 |
Why?
|
| Periodicals as Topic | 2 | 2018 | 338 | 0.770 |
Why?
|
| Preoperative Care | 6 | 2020 | 1529 | 0.760 |
Why?
|
| Leiomyomatosis | 1 | 2020 | 12 | 0.760 |
Why?
|
| Prospective Studies | 30 | 2023 | 12873 | 0.760 |
Why?
|
| Urinary Diversion | 2 | 2013 | 69 | 0.760 |
Why?
|
| Bronchial Fistula | 1 | 2020 | 37 | 0.750 |
Why?
|
| Uterine Cervical Dysplasia | 2 | 2022 | 219 | 0.750 |
Why?
|
| Bupivacaine | 1 | 2020 | 68 | 0.730 |
Why?
|
| Hysterectomy, Vaginal | 3 | 2017 | 33 | 0.720 |
Why?
|
| Acetaminophen | 1 | 2020 | 116 | 0.710 |
Why?
|
| Neoadjuvant Therapy | 10 | 2023 | 4975 | 0.710 |
Why?
|
| Vascular Neoplasms | 1 | 2020 | 114 | 0.690 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2020 | 126 | 0.690 |
Why?
|
| Anesthetics, Local | 1 | 2020 | 163 | 0.680 |
Why?
|
| Wound Healing | 2 | 2020 | 815 | 0.680 |
Why?
|
| Social Media | 1 | 2023 | 203 | 0.670 |
Why?
|
| Practice Guidelines as Topic | 7 | 2021 | 2403 | 0.660 |
Why?
|
| Surgical Oncology | 2 | 2019 | 190 | 0.650 |
Why?
|
| Uterus | 2 | 2016 | 678 | 0.650 |
Why?
|
| Guideline Adherence | 3 | 2019 | 636 | 0.630 |
Why?
|
| Antineoplastic Agents, Hormonal | 3 | 2017 | 840 | 0.630 |
Why?
|
| Editorial Policies | 1 | 2018 | 87 | 0.630 |
Why?
|
| Tumor Burden | 3 | 2020 | 1987 | 0.620 |
Why?
|
| Carcinosarcoma | 4 | 2023 | 146 | 0.610 |
Why?
|
| Practice Patterns, Physicians' | 6 | 2020 | 1303 | 0.610 |
Why?
|
| Tomography, X-Ray Computed | 14 | 2020 | 7551 | 0.600 |
Why?
|
| Disease-Free Survival | 27 | 2023 | 10001 | 0.600 |
Why?
|
| Surgical Wound Dehiscence | 2 | 2010 | 129 | 0.590 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2020 | 551 | 0.570 |
Why?
|
| Positron-Emission Tomography | 5 | 2014 | 2173 | 0.570 |
Why?
|
| Uterine Artery | 1 | 2016 | 34 | 0.560 |
Why?
|
| Quality Improvement | 4 | 2020 | 851 | 0.540 |
Why?
|
| Postoperative Period | 5 | 2021 | 665 | 0.540 |
Why?
|
| Vagina | 4 | 2011 | 317 | 0.530 |
Why?
|
| Carcinoma in Situ | 2 | 2017 | 487 | 0.530 |
Why?
|
| Standard of Care | 4 | 2023 | 243 | 0.530 |
Why?
|
| Workload | 2 | 2018 | 198 | 0.520 |
Why?
|
| Adolescent | 29 | 2021 | 31252 | 0.500 |
Why?
|
| Pregnancy Outcome | 4 | 2021 | 643 | 0.500 |
Why?
|
| Ovariectomy | 5 | 2015 | 330 | 0.500 |
Why?
|
| Randomized Controlled Trials as Topic | 8 | 2023 | 2594 | 0.500 |
Why?
|
| Pregnancy Complications, Neoplastic | 4 | 2021 | 222 | 0.490 |
Why?
|
| Adenocarcinoma, Mucinous | 2 | 2010 | 436 | 0.490 |
Why?
|
| Rectum | 1 | 2016 | 467 | 0.480 |
Why?
|
| Neoplasm Seeding | 2 | 2004 | 66 | 0.480 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 15 | 2021 | 15862 | 0.470 |
Why?
|
| Health Status Indicators | 1 | 2015 | 224 | 0.470 |
Why?
|
| Genital Diseases, Female | 2 | 2012 | 60 | 0.470 |
Why?
|
| Chemotherapy, Adjuvant | 10 | 2023 | 3890 | 0.470 |
Why?
|
| Hernia | 1 | 2013 | 46 | 0.460 |
Why?
|
| Patient Outcome Assessment | 1 | 2015 | 245 | 0.460 |
Why?
|
| Venous Thrombosis | 3 | 2017 | 384 | 0.460 |
Why?
|
| Urinary Reservoirs, Continent | 1 | 2013 | 31 | 0.450 |
Why?
|
| Fertility | 5 | 2009 | 336 | 0.450 |
Why?
|
| Feasibility Studies | 9 | 2021 | 2292 | 0.440 |
Why?
|
| Cost of Illness | 2 | 2020 | 498 | 0.440 |
Why?
|
| Colon | 1 | 2016 | 670 | 0.430 |
Why?
|
| Cystadenocarcinoma | 1 | 2012 | 21 | 0.430 |
Why?
|
| Follow-Up Studies | 21 | 2019 | 14889 | 0.420 |
Why?
|
| Tomography, Emission-Computed | 1 | 2013 | 310 | 0.420 |
Why?
|
| Patient Discharge | 3 | 2023 | 661 | 0.420 |
Why?
|
| Colostomy | 2 | 2008 | 70 | 0.410 |
Why?
|
| Cystadenocarcinoma, Serous | 8 | 2015 | 486 | 0.410 |
Why?
|
| Aorta | 3 | 2010 | 692 | 0.410 |
Why?
|
| Pain Measurement | 3 | 2020 | 953 | 0.410 |
Why?
|
| Endometrial Hyperplasia | 3 | 2018 | 112 | 0.400 |
Why?
|
| Antiemetics | 1 | 2012 | 125 | 0.400 |
Why?
|
| Quality of Life | 8 | 2023 | 4532 | 0.400 |
Why?
|
| Retinoblastoma-Like Protein p130 | 1 | 2010 | 18 | 0.390 |
Why?
|
| Phytohemagglutinins | 1 | 2010 | 71 | 0.390 |
Why?
|
| Cystadenoma | 1 | 2010 | 26 | 0.390 |
Why?
|
| Analgesics | 2 | 2022 | 390 | 0.390 |
Why?
|
| Acetylglucosamine | 1 | 2010 | 25 | 0.390 |
Why?
|
| Self Report | 1 | 2015 | 756 | 0.390 |
Why?
|
| Observational Studies as Topic | 3 | 2020 | 140 | 0.390 |
Why?
|
| N-Acetylglucosaminyltransferases | 1 | 2010 | 46 | 0.380 |
Why?
|
| Endometrium | 2 | 2019 | 470 | 0.380 |
Why?
|
| Lectins | 1 | 2010 | 151 | 0.380 |
Why?
|
| Pregnancy | 15 | 2024 | 7573 | 0.380 |
Why?
|
| Algorithms | 9 | 2021 | 3890 | 0.380 |
Why?
|
| Neoplasm Invasiveness | 11 | 2020 | 3981 | 0.360 |
Why?
|
| Vulvar Diseases | 2 | 2004 | 17 | 0.360 |
Why?
|
| Multimodal Imaging | 1 | 2014 | 550 | 0.360 |
Why?
|
| Survival Rate | 18 | 2021 | 12221 | 0.350 |
Why?
|
| Video-Assisted Surgery | 1 | 2009 | 28 | 0.350 |
Why?
|
| Cohort Studies | 16 | 2022 | 9244 | 0.340 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2010 | 192 | 0.330 |
Why?
|
| Consensus | 2 | 2024 | 978 | 0.330 |
Why?
|
| Histiocytosis, Langerhans-Cell | 3 | 2004 | 261 | 0.330 |
Why?
|
| Anesthesia | 2 | 2022 | 296 | 0.320 |
Why?
|
| Broad Ligament | 1 | 2007 | 6 | 0.310 |
Why?
|
| Developing Countries | 4 | 2021 | 315 | 0.310 |
Why?
|
| Perioperative Period | 4 | 2019 | 155 | 0.310 |
Why?
|
| Body Mass Index | 8 | 2020 | 2203 | 0.310 |
Why?
|
| Adenocarcinoma, Clear Cell | 5 | 2017 | 178 | 0.310 |
Why?
|
| Fluorodeoxyglucose F18 | 6 | 2019 | 1226 | 0.310 |
Why?
|
| Clinical Competence | 5 | 2018 | 1270 | 0.310 |
Why?
|
| Smoking | 2 | 2019 | 2440 | 0.300 |
Why?
|
| Prophylactic Surgical Procedures | 2 | 2017 | 23 | 0.300 |
Why?
|
| Counseling | 2 | 2020 | 381 | 0.300 |
Why?
|
| Blood Transfusion | 5 | 2019 | 583 | 0.290 |
Why?
|
| Carboplatin | 7 | 2023 | 823 | 0.290 |
Why?
|
| Hysteroscopy | 1 | 2007 | 51 | 0.290 |
Why?
|
| Salpingo-oophorectomy | 3 | 2021 | 50 | 0.290 |
Why?
|
| Positron Emission Tomography Computed Tomography | 3 | 2023 | 833 | 0.290 |
Why?
|
| Margins of Excision | 2 | 2020 | 285 | 0.280 |
Why?
|
| Lung Diseases | 1 | 2012 | 717 | 0.280 |
Why?
|
| Appendix | 1 | 2006 | 41 | 0.280 |
Why?
|
| Risk Factors | 16 | 2023 | 17523 | 0.280 |
Why?
|
| Splenectomy | 1 | 2006 | 158 | 0.280 |
Why?
|
| Splenic Neoplasms | 1 | 2006 | 119 | 0.280 |
Why?
|
| Patient Safety | 1 | 2012 | 649 | 0.270 |
Why?
|
| Carcinoma, Papillary | 3 | 2015 | 584 | 0.270 |
Why?
|
| Urinary Bladder | 1 | 2009 | 575 | 0.270 |
Why?
|
| Membrane Glycoproteins | 1 | 2010 | 1073 | 0.270 |
Why?
|
| Appendectomy | 1 | 2006 | 124 | 0.260 |
Why?
|
| Incidence | 7 | 2021 | 5673 | 0.260 |
Why?
|
| Vaginal Neoplasms | 4 | 2010 | 152 | 0.260 |
Why?
|
| Choriocarcinoma | 2 | 2023 | 47 | 0.260 |
Why?
|
| Obesity | 5 | 2020 | 2884 | 0.260 |
Why?
|
| Sigmoid Neoplasms | 1 | 2004 | 18 | 0.250 |
Why?
|
| Gelatin Sponge, Absorbable | 1 | 2004 | 9 | 0.250 |
Why?
|
| Age Factors | 9 | 2019 | 5377 | 0.250 |
Why?
|
| CA-125 Antigen | 2 | 2017 | 226 | 0.250 |
Why?
|
| Abdomen | 2 | 2019 | 332 | 0.250 |
Why?
|
| Vacuum | 1 | 2004 | 42 | 0.240 |
Why?
|
| Tissue Adhesives | 1 | 2004 | 51 | 0.240 |
Why?
|
| Ovary | 3 | 2015 | 668 | 0.240 |
Why?
|
| Sex Cord-Gonadal Stromal Tumors | 1 | 2004 | 35 | 0.240 |
Why?
|
| Predictive Value of Tests | 7 | 2019 | 4892 | 0.240 |
Why?
|
| Gestational Trophoblastic Disease | 1 | 2023 | 23 | 0.230 |
Why?
|
| Medroxyprogesterone Acetate | 1 | 2023 | 55 | 0.230 |
Why?
|
| Paclitaxel | 7 | 2021 | 1996 | 0.230 |
Why?
|
| Triazoles | 1 | 2008 | 617 | 0.230 |
Why?
|
| Genes, p53 | 3 | 2004 | 1090 | 0.230 |
Why?
|
| Nitriles | 1 | 2008 | 906 | 0.230 |
Why?
|
| Radiopharmaceuticals | 6 | 2019 | 1301 | 0.230 |
Why?
|
| Neoplasm, Residual | 6 | 2017 | 1656 | 0.230 |
Why?
|
| Asia | 1 | 2023 | 142 | 0.220 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2020 | 7702 | 0.220 |
Why?
|
| Hypertension, Pregnancy-Induced | 1 | 2024 | 72 | 0.220 |
Why?
|
| Fatigue | 3 | 2023 | 1239 | 0.220 |
Why?
|
| Neoplasms, Second Primary | 1 | 2011 | 1350 | 0.220 |
Why?
|
| Wolffian Ducts | 1 | 2002 | 24 | 0.220 |
Why?
|
| Survival Analysis | 12 | 2020 | 9180 | 0.210 |
Why?
|
| Vaginal Diseases | 1 | 2002 | 26 | 0.210 |
Why?
|
| Cisplatin | 4 | 2011 | 2432 | 0.210 |
Why?
|
| Neoplasms | 3 | 2023 | 15193 | 0.210 |
Why?
|
| Mass Screening | 1 | 2010 | 1509 | 0.210 |
Why?
|
| Papillomaviridae | 2 | 2021 | 624 | 0.210 |
Why?
|
| Leiomyosarcoma | 2 | 2016 | 223 | 0.200 |
Why?
|
| Neuroblastoma | 1 | 2007 | 686 | 0.200 |
Why?
|
| Colon, Sigmoid | 1 | 2001 | 42 | 0.200 |
Why?
|
| Dexmedetomidine | 1 | 2022 | 85 | 0.200 |
Why?
|
| Cystadenocarcinoma, Papillary | 1 | 2001 | 82 | 0.200 |
Why?
|
| Texas | 10 | 2018 | 6311 | 0.200 |
Why?
|
| Pre-Eclampsia | 1 | 2024 | 212 | 0.200 |
Why?
|
| Intestinal Diseases | 1 | 2002 | 121 | 0.200 |
Why?
|
| Employment | 1 | 2021 | 129 | 0.190 |
Why?
|
| Heparin | 1 | 2023 | 360 | 0.190 |
Why?
|
| Gynecological Examination | 1 | 2020 | 6 | 0.190 |
Why?
|
| Prognosis | 18 | 2019 | 21713 | 0.190 |
Why?
|
| Single-Blind Method | 2 | 2020 | 409 | 0.190 |
Why?
|
| Obesity, Morbid | 2 | 2017 | 224 | 0.190 |
Why?
|
| Unconsciousness | 1 | 2020 | 21 | 0.190 |
Why?
|
| Intestinal Perforation | 1 | 2001 | 102 | 0.190 |
Why?
|
| Antineoplastic Agents | 6 | 2017 | 14289 | 0.190 |
Why?
|
| Neoplasm Grading | 6 | 2016 | 1742 | 0.190 |
Why?
|
| Paresis | 1 | 2020 | 54 | 0.190 |
Why?
|
| Dizziness | 1 | 2020 | 47 | 0.190 |
Why?
|
| Hospitalization | 2 | 2023 | 2083 | 0.190 |
Why?
|
| Pericardium | 1 | 2001 | 157 | 0.180 |
Why?
|
| Benchmarking | 2 | 2023 | 273 | 0.180 |
Why?
|
| Logistic Models | 3 | 2012 | 3441 | 0.180 |
Why?
|
| Papillomavirus Infections | 3 | 2021 | 980 | 0.180 |
Why?
|
| Cyclins | 1 | 2001 | 456 | 0.180 |
Why?
|
| Mesothelioma | 1 | 2005 | 544 | 0.180 |
Why?
|
| Education, Medical, Graduate | 3 | 2015 | 671 | 0.180 |
Why?
|
| Coronavirus | 1 | 2020 | 40 | 0.180 |
Why?
|
| Glioblastoma | 1 | 2010 | 1797 | 0.180 |
Why?
|
| Administration, Intravenous | 1 | 2020 | 249 | 0.180 |
Why?
|
| Japan | 1 | 2020 | 227 | 0.180 |
Why?
|
| Artificial Intelligence | 1 | 2024 | 388 | 0.180 |
Why?
|
| Congresses as Topic | 1 | 2021 | 298 | 0.180 |
Why?
|
| Premature Birth | 2 | 2021 | 407 | 0.180 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2001 | 476 | 0.170 |
Why?
|
| Premenopause | 2 | 2016 | 131 | 0.170 |
Why?
|
| Risk Adjustment | 2 | 2016 | 83 | 0.170 |
Why?
|
| Risk Assessment | 5 | 2020 | 6869 | 0.170 |
Why?
|
| Statistics, Nonparametric | 2 | 2012 | 980 | 0.170 |
Why?
|
| Vena Cava, Inferior | 1 | 2020 | 190 | 0.170 |
Why?
|
| Radiation Injuries | 2 | 2010 | 1411 | 0.170 |
Why?
|
| Health Care Costs | 3 | 2019 | 674 | 0.170 |
Why?
|
| Propranolol | 1 | 2019 | 156 | 0.170 |
Why?
|
| Carcinoma, Small Cell | 2 | 2015 | 408 | 0.170 |
Why?
|
| Ketamine | 1 | 2022 | 234 | 0.170 |
Why?
|
| Fetal Viability | 1 | 2018 | 29 | 0.160 |
Why?
|
| Pain Management | 2 | 2022 | 668 | 0.160 |
Why?
|
| Computed Tomography Angiography | 1 | 2020 | 234 | 0.160 |
Why?
|
| Medicare | 1 | 2023 | 860 | 0.160 |
Why?
|
| Liposomes | 1 | 2020 | 684 | 0.160 |
Why?
|
| Perineum | 1 | 2018 | 107 | 0.160 |
Why?
|
| Cancer Care Facilities | 3 | 2018 | 884 | 0.160 |
Why?
|
| Case-Control Studies | 5 | 2021 | 6100 | 0.160 |
Why?
|
| Multivariate Analysis | 3 | 2017 | 4298 | 0.160 |
Why?
|
| Immunohistochemistry | 7 | 2018 | 7548 | 0.160 |
Why?
|
| Cross-Sectional Studies | 3 | 2023 | 4314 | 0.160 |
Why?
|
| Intrauterine Devices, Medicated | 1 | 2018 | 32 | 0.160 |
Why?
|
| Heart Atria | 1 | 2020 | 352 | 0.160 |
Why?
|
| Sensitivity and Specificity | 6 | 2017 | 4971 | 0.150 |
Why?
|
| Levonorgestrel | 1 | 2018 | 49 | 0.150 |
Why?
|
| Platinum Compounds | 2 | 2015 | 131 | 0.150 |
Why?
|
| Risk | 3 | 2022 | 1972 | 0.150 |
Why?
|
| Color | 1 | 2017 | 66 | 0.150 |
Why?
|
| Data Collection | 3 | 2009 | 620 | 0.150 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2019 | 323 | 0.150 |
Why?
|
| Uterine Hemorrhage | 2 | 2014 | 59 | 0.150 |
Why?
|
| Pilot Projects | 4 | 2021 | 2803 | 0.150 |
Why?
|
| Biomarkers, Tumor | 4 | 2011 | 10331 | 0.150 |
Why?
|
| Genes, BRCA2 | 2 | 2017 | 309 | 0.150 |
Why?
|
| Mismatch Repair Endonuclease PMS2 | 1 | 2016 | 47 | 0.150 |
Why?
|
| Fluorescence | 1 | 2017 | 195 | 0.150 |
Why?
|
| Alanine | 1 | 2017 | 240 | 0.140 |
Why?
|
| Bartholin's Glands | 1 | 2016 | 5 | 0.140 |
Why?
|
| Administration, Oral | 1 | 2020 | 1544 | 0.140 |
Why?
|
| Triazines | 1 | 2017 | 117 | 0.140 |
Why?
|
| Genes, BRCA1 | 2 | 2017 | 387 | 0.140 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2015 | 2231 | 0.140 |
Why?
|
| Program Development | 1 | 2017 | 261 | 0.140 |
Why?
|
| Sexual Dysfunctions, Psychological | 1 | 2016 | 70 | 0.140 |
Why?
|
| Fallopian Tubes | 1 | 2016 | 119 | 0.140 |
Why?
|
| Fluorescein Angiography | 1 | 2016 | 139 | 0.140 |
Why?
|
| Urachal Cyst | 1 | 1995 | 6 | 0.140 |
Why?
|
| Torsion, Mechanical | 1 | 2015 | 8 | 0.130 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2016 | 129 | 0.130 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2016 | 108 | 0.130 |
Why?
|
| Recovery of Function | 1 | 2019 | 703 | 0.130 |
Why?
|
| Surgical Procedures, Operative | 1 | 2019 | 383 | 0.130 |
Why?
|
| Ovarian Diseases | 1 | 2015 | 54 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 1995 | 181 | 0.130 |
Why?
|
| Adenosarcoma | 1 | 2014 | 16 | 0.130 |
Why?
|
| Hypercalcemia | 1 | 2015 | 137 | 0.130 |
Why?
|
| Thoracic Surgery, Video-Assisted | 1 | 2016 | 209 | 0.130 |
Why?
|
| Patient Satisfaction | 3 | 2016 | 915 | 0.120 |
Why?
|
| BRCA2 Protein | 1 | 2016 | 358 | 0.120 |
Why?
|
| Echocardiography | 1 | 2020 | 1182 | 0.120 |
Why?
|
| Betacoronavirus | 1 | 2020 | 527 | 0.120 |
Why?
|
| Trisomy | 1 | 1995 | 231 | 0.120 |
Why?
|
| Hypesthesia | 1 | 2014 | 22 | 0.120 |
Why?
|
| Blood Vessels | 1 | 2015 | 217 | 0.120 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2016 | 221 | 0.120 |
Why?
|
| Medical Records | 4 | 2014 | 415 | 0.120 |
Why?
|
| Lymphatic Vessels | 1 | 2015 | 143 | 0.120 |
Why?
|
| Propensity Score | 3 | 2021 | 750 | 0.120 |
Why?
|
| Elective Surgical Procedures | 2 | 2022 | 250 | 0.120 |
Why?
|
| Precancerous Conditions | 2 | 2018 | 1058 | 0.120 |
Why?
|
| Longitudinal Studies | 4 | 2020 | 1945 | 0.120 |
Why?
|
| Argentina | 1 | 2013 | 72 | 0.120 |
Why?
|
| Deoxycytidine | 2 | 2010 | 1353 | 0.120 |
Why?
|
| BRCA1 Protein | 1 | 2016 | 493 | 0.120 |
Why?
|
| Acute Kidney Injury | 1 | 2021 | 739 | 0.120 |
Why?
|
| Ultrasonography | 1 | 2020 | 1863 | 0.120 |
Why?
|
| Combined Modality Therapy | 8 | 2023 | 8865 | 0.120 |
Why?
|
| Biopsy | 2 | 2012 | 3443 | 0.120 |
Why?
|
| Reproducibility of Results | 5 | 2019 | 6009 | 0.120 |
Why?
|
| Activities of Daily Living | 1 | 2016 | 552 | 0.110 |
Why?
|
| Surveys and Questionnaires | 5 | 2021 | 5687 | 0.110 |
Why?
|
| Leiomyoma | 1 | 2014 | 145 | 0.110 |
Why?
|
| Punctures | 1 | 2013 | 104 | 0.110 |
Why?
|
| Pregnancy Rate | 1 | 2013 | 58 | 0.110 |
Why?
|
| Intraoperative Care | 2 | 2012 | 259 | 0.110 |
Why?
|
| Infertility, Female | 1 | 2015 | 217 | 0.110 |
Why?
|
| Occupational Diseases | 1 | 2014 | 130 | 0.110 |
Why?
|
| Organ Sparing Treatments | 1 | 2015 | 277 | 0.110 |
Why?
|
| Drug Resistance, Neoplasm | 5 | 2012 | 5178 | 0.110 |
Why?
|
| Comorbidity | 3 | 2023 | 2352 | 0.110 |
Why?
|
| Patient Positioning | 1 | 2014 | 195 | 0.110 |
Why?
|
| Prescription Fees | 1 | 2012 | 17 | 0.110 |
Why?
|
| Male | 16 | 2021 | 123000 | 0.110 |
Why?
|
| Time Factors | 8 | 2020 | 12926 | 0.110 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2012 | 66 | 0.110 |
Why?
|
| Inducible T-Cell Co-Stimulator Protein | 1 | 2012 | 76 | 0.110 |
Why?
|
| Enoxaparin | 1 | 2012 | 66 | 0.110 |
Why?
|
| Frozen Sections | 1 | 2012 | 105 | 0.100 |
Why?
|
| Mutation | 3 | 2016 | 15179 | 0.100 |
Why?
|
| Surgical Flaps | 2 | 2011 | 927 | 0.100 |
Why?
|
| Urinary Incontinence | 1 | 2013 | 149 | 0.100 |
Why?
|
| Radiotherapy | 3 | 2016 | 1824 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2021 | 6207 | 0.100 |
Why?
|
| Pulmonary Atelectasis | 1 | 2012 | 46 | 0.100 |
Why?
|
| Blood Volume | 1 | 2012 | 100 | 0.100 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 651 | 0.100 |
Why?
|
| Clinical Trials as Topic | 4 | 2016 | 3719 | 0.100 |
Why?
|
| Linear Models | 1 | 2015 | 1085 | 0.100 |
Why?
|
| Anticoagulants | 2 | 2015 | 787 | 0.100 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 715 | 0.100 |
Why?
|
| Fetal Diseases | 1 | 1995 | 388 | 0.100 |
Why?
|
| Aorta, Abdominal | 1 | 2012 | 152 | 0.100 |
Why?
|
| Taxoids | 3 | 2012 | 967 | 0.100 |
Why?
|
| Societies, Medical | 3 | 2024 | 1335 | 0.100 |
Why?
|
| Diagnostic Techniques, Obstetrical and Gynecological | 1 | 2010 | 8 | 0.100 |
Why?
|
| Groin | 3 | 2009 | 74 | 0.100 |
Why?
|
| Clinical Protocols | 1 | 2013 | 467 | 0.100 |
Why?
|
| Child | 7 | 2015 | 29154 | 0.100 |
Why?
|
| International Cooperation | 2 | 2012 | 323 | 0.100 |
Why?
|
| Pandemics | 1 | 2020 | 1559 | 0.090 |
Why?
|
| Glycosylation | 1 | 2010 | 213 | 0.090 |
Why?
|
| Health Status | 2 | 2020 | 590 | 0.090 |
Why?
|
| Pathologists | 2 | 2021 | 91 | 0.090 |
Why?
|
| Preoperative Period | 1 | 2011 | 344 | 0.090 |
Why?
|
| Ultrasonography, Prenatal | 1 | 1995 | 830 | 0.090 |
Why?
|
| Analysis of Variance | 1 | 2014 | 2307 | 0.090 |
Why?
|
| Etoposide | 2 | 2007 | 870 | 0.090 |
Why?
|
| Endothelium | 1 | 2010 | 158 | 0.090 |
Why?
|
| Paraffin Embedding | 1 | 2010 | 226 | 0.090 |
Why?
|
| Metastasectomy | 1 | 2011 | 200 | 0.090 |
Why?
|
| Smooth Muscle Tumor | 1 | 2009 | 9 | 0.090 |
Why?
|
| Trophoblastic Neoplasms | 1 | 2009 | 19 | 0.090 |
Why?
|
| Pelvic Bones | 1 | 2010 | 95 | 0.090 |
Why?
|
| Vaginal Smears | 1 | 2010 | 192 | 0.090 |
Why?
|
| Severity of Illness Index | 2 | 2019 | 4320 | 0.080 |
Why?
|
| Electrosurgery | 1 | 2008 | 28 | 0.080 |
Why?
|
| ROC Curve | 1 | 2012 | 1183 | 0.080 |
Why?
|
| Rhabdomyosarcoma | 1 | 2012 | 341 | 0.080 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2009 | 305 | 0.080 |
Why?
|
| Colpotomy | 1 | 2008 | 8 | 0.080 |
Why?
|
| Cost-Benefit Analysis | 2 | 2012 | 945 | 0.080 |
Why?
|
| Transplantation, Heterologous | 1 | 2010 | 1082 | 0.080 |
Why?
|
| Radiography | 2 | 2010 | 1904 | 0.080 |
Why?
|
| Trophoblasts | 1 | 2009 | 138 | 0.080 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2012 | 673 | 0.080 |
Why?
|
| Contraceptive Devices, Female | 1 | 2007 | 5 | 0.080 |
Why?
|
| Proportional Hazards Models | 3 | 2023 | 4988 | 0.080 |
Why?
|
| Glutathione | 1 | 2010 | 368 | 0.080 |
Why?
|
| Patient Readmission | 2 | 2023 | 548 | 0.080 |
Why?
|
| Forkhead Transcription Factors | 1 | 2012 | 778 | 0.080 |
Why?
|
| Colorectal Neoplasms | 2 | 2016 | 3578 | 0.080 |
Why?
|
| Gene Transfer Techniques | 1 | 2010 | 716 | 0.080 |
Why?
|
| Equipment Safety | 1 | 2007 | 64 | 0.080 |
Why?
|
| Adenocarcinoma, Papillary | 1 | 2008 | 69 | 0.080 |
Why?
|
| Fetal Growth Retardation | 2 | 2021 | 194 | 0.080 |
Why?
|
| Precision Medicine | 1 | 2015 | 1154 | 0.070 |
Why?
|
| Laparoscopes | 1 | 2006 | 10 | 0.070 |
Why?
|
| Endoscopy | 1 | 2010 | 479 | 0.070 |
Why?
|
| Diagnosis, Differential | 3 | 2012 | 4744 | 0.070 |
Why?
|
| Neoplasm Metastasis | 3 | 2016 | 5112 | 0.070 |
Why?
|
| Fractures, Bone | 1 | 2010 | 291 | 0.070 |
Why?
|
| Pulmonary Embolism | 1 | 2010 | 329 | 0.070 |
Why?
|
| Drug Administration Schedule | 4 | 2021 | 3472 | 0.070 |
Why?
|
| Cystadenocarcinoma, Mucinous | 1 | 2006 | 21 | 0.070 |
Why?
|
| Disease Progression | 3 | 2018 | 6682 | 0.070 |
Why?
|
| False Negative Reactions | 2 | 2019 | 275 | 0.070 |
Why?
|
| Polyethylene Glycols | 1 | 2010 | 615 | 0.070 |
Why?
|
| Bleomycin | 1 | 2007 | 467 | 0.070 |
Why?
|
| Proteasome Inhibitors | 1 | 2007 | 231 | 0.070 |
Why?
|
| Dendritic Cells | 1 | 2012 | 1085 | 0.070 |
Why?
|
| Electrocoagulation | 1 | 2006 | 65 | 0.070 |
Why?
|
| Hemostasis, Surgical | 1 | 2006 | 48 | 0.070 |
Why?
|
| Research Design | 1 | 2013 | 1544 | 0.070 |
Why?
|
| Bortezomib | 1 | 2007 | 543 | 0.070 |
Why?
|
| Pain | 1 | 2014 | 1658 | 0.070 |
Why?
|
| Boronic Acids | 1 | 2007 | 362 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2010 | 4938 | 0.070 |
Why?
|
| Carcinoma, Large Cell | 1 | 2005 | 94 | 0.060 |
Why?
|
| Mice, Nude | 2 | 2010 | 4307 | 0.060 |
Why?
|
| Camptothecin | 1 | 2007 | 517 | 0.060 |
Why?
|
| Cystectomy | 1 | 2009 | 623 | 0.060 |
Why?
|
| Urinary Fistula | 1 | 2004 | 27 | 0.060 |
Why?
|
| Lymph | 1 | 2004 | 76 | 0.060 |
Why?
|
| Pyrazines | 1 | 2007 | 495 | 0.060 |
Why?
|
| Progestins | 1 | 2004 | 87 | 0.060 |
Why?
|
| Melanoma | 3 | 2010 | 5317 | 0.060 |
Why?
|
| Fluorine Radioisotopes | 1 | 2005 | 133 | 0.060 |
Why?
|
| Anus Neoplasms | 1 | 2008 | 411 | 0.060 |
Why?
|
| Occlusive Dressings | 1 | 2004 | 14 | 0.060 |
Why?
|
| Surgical Wound Infection | 2 | 2019 | 450 | 0.060 |
Why?
|
| Spain | 1 | 2024 | 113 | 0.060 |
Why?
|
| Fluorouracil | 1 | 2008 | 1944 | 0.060 |
Why?
|
| Equipment Design | 1 | 2007 | 1204 | 0.060 |
Why?
|
| Recurrence | 2 | 2010 | 4758 | 0.060 |
Why?
|
| Pancreatectomy | 1 | 2008 | 652 | 0.060 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2006 | 328 | 0.060 |
Why?
|
| United States | 5 | 2023 | 15433 | 0.060 |
Why?
|
| Viral Vaccines | 1 | 2006 | 304 | 0.060 |
Why?
|
| Technetium Tc 99m Sulfur Colloid | 2 | 2017 | 115 | 0.060 |
Why?
|
| Langerhans Cells | 1 | 2003 | 50 | 0.060 |
Why?
|
| Papillomavirus Vaccines | 1 | 2006 | 195 | 0.060 |
Why?
|
| Piperazines | 1 | 2012 | 2101 | 0.060 |
Why?
|
| Molecular Biology | 1 | 2024 | 176 | 0.050 |
Why?
|
| Prolapse | 1 | 2002 | 13 | 0.050 |
Why?
|
| Gallbladder Neoplasms | 1 | 2005 | 245 | 0.050 |
Why?
|
| Doxorubicin | 1 | 2010 | 3005 | 0.050 |
Why?
|
| Retroperitoneal Space | 2 | 2017 | 145 | 0.050 |
Why?
|
| Prevalence | 1 | 2010 | 3260 | 0.050 |
Why?
|
| Genetic Therapy | 2 | 2014 | 1616 | 0.050 |
Why?
|
| Income | 1 | 2023 | 222 | 0.050 |
Why?
|
| Gravidity | 1 | 2021 | 19 | 0.050 |
Why?
|
| Radionuclide Imaging | 3 | 2008 | 660 | 0.050 |
Why?
|
| Meconium Aspiration Syndrome | 1 | 2021 | 15 | 0.050 |
Why?
|
| Birth Injuries | 1 | 2021 | 24 | 0.050 |
Why?
|
| Brazil | 1 | 2021 | 165 | 0.050 |
Why?
|
| Stillbirth | 1 | 2021 | 82 | 0.050 |
Why?
|
| Infant, Small for Gestational Age | 1 | 2021 | 59 | 0.050 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2001 | 367 | 0.050 |
Why?
|
| Genes, p16 | 1 | 2001 | 125 | 0.050 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2006 | 573 | 0.050 |
Why?
|
| California | 1 | 2021 | 208 | 0.050 |
Why?
|
| Abdominal Pain | 1 | 2023 | 369 | 0.050 |
Why?
|
| Cell Division | 2 | 2001 | 2489 | 0.050 |
Why?
|
| Intracranial Hemorrhages | 1 | 2021 | 121 | 0.050 |
Why?
|
| Rectal Neoplasms | 1 | 2008 | 1202 | 0.050 |
Why?
|
| Tamoxifen | 1 | 2004 | 876 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2001 | 528 | 0.050 |
Why?
|
| Morbidity | 1 | 2021 | 397 | 0.050 |
Why?
|
| Conversion to Open Surgery | 1 | 2019 | 10 | 0.050 |
Why?
|
| Thalidomide | 1 | 2003 | 569 | 0.050 |
Why?
|
| Palliative Care | 2 | 2008 | 2037 | 0.040 |
Why?
|
| Hypoxia-Ischemia, Brain | 1 | 2021 | 137 | 0.040 |
Why?
|
| Receptor, EphA2 | 1 | 2021 | 132 | 0.040 |
Why?
|
| Disease Eradication | 1 | 2020 | 36 | 0.040 |
Why?
|
| Caveolin 1 | 1 | 2021 | 204 | 0.040 |
Why?
|
| Transfection | 2 | 2001 | 2944 | 0.040 |
Why?
|
| Brain Neoplasms | 1 | 2016 | 4849 | 0.040 |
Why?
|
| Monitoring, Intraoperative | 1 | 2021 | 264 | 0.040 |
Why?
|
| Pyrimidines | 1 | 2012 | 3518 | 0.040 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2019 | 30 | 0.040 |
Why?
|
| Pharmacy Service, Hospital | 1 | 2019 | 56 | 0.040 |
Why?
|
| Hospital Charges | 1 | 2019 | 75 | 0.040 |
Why?
|
| Hospitals | 1 | 2022 | 485 | 0.040 |
Why?
|
| Clinical Laboratory Services | 1 | 2019 | 42 | 0.040 |
Why?
|
| Operative Time | 1 | 2019 | 217 | 0.040 |
Why?
|
| Aftercare | 1 | 2020 | 259 | 0.040 |
Why?
|
| Cell Cycle | 2 | 2001 | 2084 | 0.040 |
Why?
|
| Cell Line, Tumor | 2 | 2012 | 14551 | 0.040 |
Why?
|
| World Health Organization | 1 | 2020 | 316 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2010 | 5159 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 2 | 2021 | 2330 | 0.040 |
Why?
|
| Women's Health | 1 | 2020 | 205 | 0.040 |
Why?
|
| Cesarean Section | 1 | 2021 | 367 | 0.040 |
Why?
|
| Cost Savings | 1 | 2019 | 123 | 0.040 |
Why?
|
| Infant, Newborn | 2 | 2021 | 8223 | 0.040 |
Why?
|
| Blood Pressure | 1 | 2024 | 1467 | 0.040 |
Why?
|
| Ileus | 1 | 2017 | 27 | 0.040 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2004 | 716 | 0.040 |
Why?
|
| Respiration, Artificial | 1 | 2021 | 577 | 0.040 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2017 | 85 | 0.040 |
Why?
|
| Public Health | 1 | 2020 | 299 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 2 | 2001 | 5395 | 0.040 |
Why?
|
| Registries | 2 | 2021 | 2170 | 0.040 |
Why?
|
| Dasatinib | 1 | 2021 | 862 | 0.040 |
Why?
|
| Leukocytes | 1 | 2019 | 422 | 0.040 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2017 | 160 | 0.040 |
Why?
|
| Social Participation | 1 | 2016 | 20 | 0.040 |
Why?
|
| Perception | 1 | 2019 | 350 | 0.040 |
Why?
|
| Tissue Adhesions | 1 | 2017 | 60 | 0.040 |
Why?
|
| Role | 1 | 2016 | 48 | 0.040 |
Why?
|
| ErbB Receptors | 1 | 2005 | 2295 | 0.040 |
Why?
|
| Mesenteric Artery, Superior | 1 | 2017 | 71 | 0.040 |
Why?
|
| Mental Health | 1 | 2020 | 415 | 0.040 |
Why?
|
| Breast Neoplasms | 2 | 2015 | 15694 | 0.040 |
Why?
|
| Omentum | 1 | 2017 | 96 | 0.030 |
Why?
|
| Retreatment | 1 | 2017 | 452 | 0.030 |
Why?
|
| Pregnancy Complications | 1 | 2021 | 526 | 0.030 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2021 | 607 | 0.030 |
Why?
|
| Ascites | 1 | 2017 | 198 | 0.030 |
Why?
|
| Databases, Factual | 2 | 2017 | 2218 | 0.030 |
Why?
|
| Organoplatinum Compounds | 2 | 2012 | 702 | 0.030 |
Why?
|
| Adenoviridae | 1 | 2001 | 1459 | 0.030 |
Why?
|
| Receptor, ErbB-2 | 1 | 2005 | 2518 | 0.030 |
Why?
|
| Papanicolaou Test | 1 | 2016 | 141 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2001 | 1493 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2021 | 1085 | 0.030 |
Why?
|
| Simulation Training | 1 | 2017 | 149 | 0.030 |
Why?
|
| Directive Counseling | 1 | 2015 | 41 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2001 | 3639 | 0.030 |
Why?
|
| Postoperative Care | 2 | 2010 | 739 | 0.030 |
Why?
|
| Spleen | 1 | 2017 | 676 | 0.030 |
Why?
|
| Microsatellite Instability | 1 | 2016 | 400 | 0.030 |
Why?
|
| Abdominal Wall | 1 | 2017 | 184 | 0.030 |
Why?
|
| Psychometrics | 1 | 2019 | 937 | 0.030 |
Why?
|
| Intraoperative Period | 1 | 2014 | 246 | 0.030 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2017 | 473 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2018 | 1363 | 0.030 |
Why?
|
| Central America | 1 | 2013 | 29 | 0.030 |
Why?
|
| Child, Preschool | 3 | 2015 | 16273 | 0.030 |
Why?
|
| Vinblastine | 1 | 2004 | 453 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2016 | 672 | 0.030 |
Why?
|
| Cognition Disorders | 1 | 2019 | 786 | 0.030 |
Why?
|
| Pedigree | 1 | 2016 | 1890 | 0.030 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2001 | 2488 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2017 | 1529 | 0.030 |
Why?
|
| Colombia | 1 | 2012 | 66 | 0.030 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2015 | 565 | 0.030 |
Why?
|
| Hospitals, Community | 1 | 2012 | 79 | 0.030 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2016 | 592 | 0.030 |
Why?
|
| Hospitals, University | 1 | 2012 | 209 | 0.030 |
Why?
|
| Curriculum | 1 | 2017 | 860 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2017 | 2316 | 0.030 |
Why?
|
| Pneumonia | 1 | 2017 | 751 | 0.020 |
Why?
|
| Mice | 2 | 2010 | 34495 | 0.020 |
Why?
|
| Gene Expression | 1 | 2019 | 3570 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2015 | 667 | 0.020 |
Why?
|
| Apoptosis | 2 | 2001 | 7591 | 0.020 |
Why?
|
| Pubic Bone | 1 | 2010 | 16 | 0.020 |
Why?
|
| Pancreatic Neoplasms | 1 | 2008 | 5061 | 0.020 |
Why?
|
| Chemoradiotherapy | 1 | 2019 | 1946 | 0.020 |
Why?
|
| Cytokines | 1 | 2019 | 2809 | 0.020 |
Why?
|
| Acetabulum | 1 | 2010 | 38 | 0.020 |
Why?
|
| Health Expenditures | 1 | 2012 | 211 | 0.020 |
Why?
|
| Insurance Coverage | 1 | 2012 | 256 | 0.020 |
Why?
|
| Liver Neoplasms | 2 | 2009 | 4557 | 0.020 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2011 | 355 | 0.020 |
Why?
|
| Disease Management | 1 | 2015 | 1052 | 0.020 |
Why?
|
| Colposcopy | 1 | 2009 | 78 | 0.020 |
Why?
|
| Sacrum | 1 | 2010 | 132 | 0.020 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 2009 | 84 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2001 | 3552 | 0.020 |
Why?
|
| Rectovaginal Fistula | 1 | 2008 | 9 | 0.020 |
Why?
|
| Decision Making | 1 | 2016 | 1287 | 0.020 |
Why?
|
| Overweight | 1 | 2012 | 484 | 0.020 |
Why?
|
| Graft Survival | 1 | 2011 | 1062 | 0.020 |
Why?
|
| Imatinib Mesylate | 1 | 2012 | 1665 | 0.020 |
Why?
|
| Animals | 2 | 2010 | 59536 | 0.020 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2009 | 408 | 0.020 |
Why?
|
| Menopause, Premature | 1 | 2007 | 17 | 0.020 |
Why?
|
| Capecitabine | 1 | 2008 | 388 | 0.020 |
Why?
|
| Bone Density | 1 | 2010 | 476 | 0.020 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2014 | 1248 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2009 | 1165 | 0.020 |
Why?
|
| Reoperation | 1 | 2011 | 1382 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2010 | 1391 | 0.020 |
Why?
|
| Benzamides | 1 | 2012 | 1832 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2011 | 1555 | 0.020 |
Why?
|
| Physical Examination | 1 | 2007 | 299 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2012 | 3033 | 0.020 |
Why?
|
| Probability | 1 | 2007 | 866 | 0.020 |
Why?
|
| Urinary Bladder Fistula | 1 | 2004 | 13 | 0.020 |
Why?
|
| Ureteral Diseases | 1 | 2004 | 16 | 0.020 |
Why?
|
| Hot Temperature | 1 | 2006 | 281 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2017 | 2992 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2009 | 1144 | 0.020 |
Why?
|
| Mixed Tumor, Mullerian | 1 | 2004 | 37 | 0.020 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2005 | 215 | 0.020 |
Why?
|
| Urethral Diseases | 1 | 2004 | 36 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2007 | 1382 | 0.020 |
Why?
|
| Injections, Intraperitoneal | 1 | 2004 | 197 | 0.020 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2008 | 690 | 0.020 |
Why?
|
| Rectus Abdominis | 1 | 2005 | 100 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2007 | 1290 | 0.020 |
Why?
|
| Adenoviruses, Human | 1 | 2004 | 181 | 0.010 |
Why?
|
| Drug Delivery Systems | 1 | 2008 | 669 | 0.010 |
Why?
|
| Early Detection of Cancer | 1 | 2011 | 1258 | 0.010 |
Why?
|
| Rosaniline Dyes | 1 | 2004 | 108 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2009 | 2927 | 0.010 |
Why?
|
| Cyclooxygenase 2 | 1 | 2005 | 483 | 0.010 |
Why?
|
| Mothers | 1 | 2006 | 410 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2021 | 11965 | 0.010 |
Why?
|
| Brachytherapy | 1 | 2009 | 977 | 0.010 |
Why?
|
| Adaptation, Psychological | 1 | 2007 | 764 | 0.010 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2008 | 1299 | 0.010 |
Why?
|
| beta-Galactosidase | 1 | 2001 | 211 | 0.010 |
Why?
|
| Salvage Therapy | 1 | 2008 | 2054 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2001 | 869 | 0.010 |
Why?
|
| Receptors, Progesterone | 1 | 2005 | 1392 | 0.010 |
Why?
|
| Adjuvants, Immunologic | 1 | 2003 | 657 | 0.010 |
Why?
|
| Receptors, Estrogen | 1 | 2005 | 2086 | 0.010 |
Why?
|
| Bone Neoplasms | 1 | 2009 | 2576 | 0.010 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2012 | 4757 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2001 | 3536 | 0.010 |
Why?
|
| Cell Survival | 1 | 2001 | 3045 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2005 | 2819 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2009 | 11538 | 0.000 |
Why?
|